Cancer Immunology, Immunotherapy
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 5.8 | Q1 | 80.2% | 1.805 | Q1 | 94.3% |
| 2024 | 5.1 | Q1 | 79.4% | 1.716 | Q1 | 93.9% |
| 2023 | 4.6 | Q1 | 73.8% | 1.663 | Q1 | 93.9% |
| 2022 | 5.8 | Q1 | 78.3% | 1.663 | Q1 | 94.2% |
| 2021 | 6.6 | Q2 | 79.4% | 1.723 | Q1 | 94.6% |
| 2020 | — | — | 2.389 | Q1 | 96.7% | |
| 2019 | — | — | 1.957 | Q1 | 95.5% | |
| 2018 | — | — | 2.085 | Q1 | 95.3% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
0340-7004
ISSN
1432-0851
country
DEcoverage
1976-2026